XML 71 R60.htm IDEA: XBRL DOCUMENT v3.25.2
FAIR VALUE - Narrative (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
Rate
Jun. 30, 2024
USD ($)
Dec. 31, 2024
USD ($)
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]          
Contingent consideration, current portion $ 726   $ 726   $ 726
Derivative liability 200   200   200
Spectrum Pharmaceuticals, Inc.          
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]          
Contingent consideration 0   0   0
Change in fair value of contingent consideration 0 $ 0 0 $ 0  
Zyla Merger          
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]          
Change in fair value of contingent consideration 0 $ 0 0 $ 0  
Level 2          
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]          
Debt conversion option value 36,300   36,300   34,800
Convertible notes, par value $ 40,000   $ 40,000   40,000
Option Pricing Model | Credit Spread          
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]          
Embedded derivative liability, measurement input 0.105   0.105    
INDOCIN | Zyla Merger          
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]          
Contingent payment consideration, future royalties covenant, product net sales (over)     $ 20,000    
Contingent consideration, royalty percentage | Rate     20.00%    
Contingent consideration, current portion $ 700   $ 700   $ 700